The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers.
 
Nataliya Volodymyrivna Uboha
Stock and Other Ownership Interests - Exact Sciences (I); Natera (I)
Consulting or Advisory Role - Aptitude Health; Arcus Biosciences; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; BostonGene; Bristol Myers Squibb Foundation; Bristol-Myers Squibb/Roche; Eisai/MSD; Elevation Oncology; GRAIL; Helsinn Therapeutics; ipsen; Ipsen; Lilly; Pfizer; Strata Oncology
Research Funding - Arcus Biosciences (Inst); EMD Serono (Inst); ipsen (Inst)
 
Yvonne M. Saenger
No Relationships to Disclose
 
Olatunji B. Alese
Consulting or Advisory Role - AADi; Bristol-Myers Squibb; Pfizer; Seagen; Seagen; Taiho Oncology; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corcept Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Ipsen (Inst); PCI Biotech (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst)
 
Dae Won Kim
Honoraria - AstraZeneca
Research Funding - Bold Therapeutics
 
Lei Zheng
Stock and Other Ownership Interests - Alphamab; Mingruizhiyao; Z and L International Medical
Consulting or Advisory Role - Alphamab; Ambrx; AstraZeneca; BioArdis; Biosynergies; Coherent; datarevive; Foundation Medicine; Johnson & Johnson/Janssen; Merck; Merrimack; Mingruizhiyao; NovaGenesis; novarock; Snow Lake Capital; Xilio Therapeutics
Research Funding - Amgen; AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Gradalis; Halozyme; InxMed; ITeos Therapeutics; Merck; NovaRock
Patents, Royalties, Other Intellectual Property - GVAX, licensed to Aduro Biotech.
Other Relationship - QED Therapeutics
 
Jorge Chaves
No Relationships to Disclose
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Jun Gong
Honoraria - Amgen; Astellas Pharma; AVEO; Basilea Pharmaceutical; Bayer; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono; Exelixis; HalioDx; Incyte; Janssen Biotech; Natera; Pfizer/Myovant; QED Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; AVEO; Basilea; Bayer; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono/Merck; Exelixis; HalioDx; Incyte; Janssen Biotech; MJH Life Sciences; Natera; OncLive/MJH Life Sciences; Pfizer/Myovant; QED Therapeutics; Seagen
Patents, Royalties, Other Intellectual Property - PCT/US2021/043961 provisional patent on glutamine and cancer; U.S. Provisional Application Serial No. 63/315,895 on methylated ctDNA markers
 
Zhaohui Jin
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); QED Therapeutics (Inst)
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Allarity Therapeutics (Inst); Apros Therapeutics; Aptevo Therapeutics (Inst); Arcus Biosciences; Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); Aulos Bioscience (Inst); BioBank Online (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; Cellgene Corp. (Inst); CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corbus Pharmaceuticals (Inst); Corvus Pharmaceuticals; CUE BioPharma (Inst); Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; GI Innovation (Inst); Glenmark Specialty SA (Inst); Harbour BioMed (Inst); I-Mab (Inst); IconOVir Bio (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; MBrace Therapeutics Inc. (Inst); Medikine (Inst); Merck (Inst); Modena TX (Inst); Molecular Templates (Inst); MT Group (Inst); Multitude Therapeutics Inc (Inst); NextCure (Inst); Nuvation Bio (Inst); PBD Biologics LTD (Inst); PEEL Therapeutics (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Qurgen (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Revolution Medicines Inc. (Inst); RiboScience (Inst); Sairopa (Inst); Seagen; Sequenom (Inst); Simcere (Inst); SK Life Sciences (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Nashat Gabrail
Consulting or Advisory Role - Celgene; Chemiocare
Speakers' Bureau - Janssen Oncology; Janssen Oncology; Janssen Oncology; Karyopharm Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tesaro/GSK
Research Funding - Amgen (Inst); Bayer (Inst); Chemiocare (Inst); Chemiocare (Inst); Kartos Therapeutics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Oncology Supply
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Angela Tatiana Alistar
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Merck
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck; seagen
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Christopher Chen
Consulting or Advisory Role - Boxer Capital; Globepoint Global
Research Funding - ADC Therapeutics (Inst); Gilead Sciences (Inst); Kinnate Biopharma (Inst); Mersana (Inst); ORIC Pharmaceuticals (Inst); Palleon Pharmaceuticals (Inst); Pionyr Therapeutics (Inst); Rain Oncology (Inst); Seagen (Inst); Takeda (Inst)
 
Laura Agensky
Employment - Cue Biopharma
 
Apollina Goel
Employment - Cue Biopharma
 
Steven Margossian
Employment - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
 
Steven N Quayle
Employment - Cue Biopharma; Pieris Pharmaceuticals (I)
Stock and Other Ownership Interests - Cue Biopharma; IQVIA (I); Pieris Pharmaceuticals (I)
 
Matteo Levisetti
Employment - Cue Biopharma
Leadership - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma; Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Cue Biopharma
 
J. Eva Selfridge
Research Funding - Arcus Biosciences (Inst); BioAtla (Inst); CUE Biopharma (Inst); Tizona Therapeutics, Inc. (Inst); Vigeo Therapeutics (Inst)
Travel, Accommodations, Expenses - Arcus Biosciences; DAVA Pharmaceuticals